JP2013514986A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514986A5
JP2013514986A5 JP2012544869A JP2012544869A JP2013514986A5 JP 2013514986 A5 JP2013514986 A5 JP 2013514986A5 JP 2012544869 A JP2012544869 A JP 2012544869A JP 2012544869 A JP2012544869 A JP 2012544869A JP 2013514986 A5 JP2013514986 A5 JP 2013514986A5
Authority
JP
Japan
Prior art keywords
combination according
dimethoxy
phenyl
pharmaceutically acceptable
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012544869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514986A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060956 external-priority patent/WO2011075620A1/en
Publication of JP2013514986A publication Critical patent/JP2013514986A/ja
Publication of JP2013514986A5 publication Critical patent/JP2013514986A5/ja
Pending legal-status Critical Current

Links

JP2012544869A 2009-12-18 2010-12-17 血液癌の処置方法 Pending JP2013514986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28783109P 2009-12-18 2009-12-18
US61/287,831 2009-12-18
PCT/US2010/060956 WO2011075620A1 (en) 2009-12-18 2010-12-17 Method for treating haematological cancers

Publications (2)

Publication Number Publication Date
JP2013514986A JP2013514986A (ja) 2013-05-02
JP2013514986A5 true JP2013514986A5 (cg-RX-API-DMAC10.html) 2014-02-06

Family

ID=43569244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544869A Pending JP2013514986A (ja) 2009-12-18 2010-12-17 血液癌の処置方法

Country Status (4)

Country Link
US (1) US20120258940A1 (cg-RX-API-DMAC10.html)
EP (1) EP2512476A1 (cg-RX-API-DMAC10.html)
JP (1) JP2013514986A (cg-RX-API-DMAC10.html)
WO (1) WO2011075620A1 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2830626B1 (en) 2012-03-30 2019-01-02 Novartis AG Fgfr inhibitor for use in the treatment of hypophosphatemic disorders
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
US20170196888A1 (en) * 2014-06-25 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
CA3128084A1 (en) * 2019-02-14 2020-08-20 Bridgene Biosciences, Inc. Fgfr inhibitors for the treatment of cancer
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
AU2020272861A1 (en) * 2019-04-10 2021-10-07 Dana-Farber Cancer Institute, Inc. Degraders of fibroblast growth factor receptor 2 (FGFR2)
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
ME00011A (me) * 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
CA2728063A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436

Similar Documents

Publication Publication Date Title
IL266894B (en) Preparation of (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts
HRP20160287T1 (hr) Antagonisti cgrp receptora
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
NZ606246A (en) Anticancer derivatives, preparation thereof and therapeutic use thereof
BR112014009092A2 (pt) dispersão sólida
IL203206A (en) 2-Amino Derivatives, 4-Amido Quinazoline, Drugs Containing and Using Theirs, and Process for Manufacturing
IL205665A (en) The history of terroiril, the process of preparing them, the drugs containing them and their use in the preparation of drugs
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
EP2696679A4 (en) 2'-CYAN SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
IL209121A (en) Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP2012255026A5 (cg-RX-API-DMAC10.html)
IL209267A (en) Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug
JP2012236857A5 (cg-RX-API-DMAC10.html)
IL207684A (en) Preserved indole history, a method for making these histories, drugs containing these histories, and their use in making drugs
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
EP2635260A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
EP2717914A4 (en) DELAYED FORMULATIONS FOR THE ADMINISTRATION OF PROTEINS AND FOR THEIR MANUFACTURE
IL202248A (en) Aster 4– (3-Methoxy-4-Chloro-Phenyl) Piprazine-1-Il of Acid 3– (Imidazol-2-Il) -Pyrazolo] 4,3– [b Pyridine – 1-Acetic, Methods of preparation and use in preparation of medicinal products
FR2937972B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2648697A4 (en) METHOD FOR THE PRODUCTION OF MINIEMULSIONS AND USE FOR THE RELEASE OF BIOACTIVE ACTIVE SUBSTANCES
WO2008067399A3 (en) Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution